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Uveitic glaucoma (UG) typically is associated with very high intraocular pressure (IOP) andmore intense optic nerve damage than
other glaucoma types.This secondary glaucoma requires an early diagnosis and adequatemanagement of both uveitis and glaucoma.
It ismandatory to identify themechanisms of IOP elevation that inmany eyes havemultiple combinedmechanisms.Management of
these patients commonly requires an interdisciplinary approach that includes a glaucoma specialist and rheumatologist to control
the inflammation and IOP. Glaucoma surgery is required early in these patients due to the high IOP usually present and is less
successful than in primary open-angle glaucoma. Recurrent uveitic episodes,multiplemechanism, and the complications associated
with uveitis make surgical management of UG challenging. In this review, the management and treatment of UG are updated to
clarify the pathogenesis and prevent optic nerve damage.
1. Introduction
Patients with uveitis have an increased risk of intraocular
pressure (IOP) elevation not only because of the disease but
also as a side effect of corticosteroid use [1].
Uveitic glaucoma (UG) includes a range of disorders
whose common end result is glaucomatous optic nerve and
visual field damage. Compared with primary open-angle
glaucoma (POAG), patients with UG are younger and IOP
values are higher with acute elevations and varying responses
to antiglaucomatous drugs.
The mechanism of UG is complex (different open-
angle and closed-angle mechanisms can coexist in the same
patient), and management requires careful diagnosis and
adequate control of both IOP and inflammation. A multidis-
ciplinary approach is necessary in many cases to achieve a
successful outcome.
The very high IOP and the complex interrelation with
ocular inflammation explain why many patients with UG
require glaucoma filtering surgery sometimes combined with
phacoemulsification. Strict control of inflammation increases
the chance of success, but surgery for UG historically has
been considered refractory because of the increased risk
of failure. Otherwise, ciliary body inflammation can result
in prolonged postoperative hypotony, making the results of
filtering procedures more unpredictable.
This update is intended to assist ophthalmologistswho are
managing patients with UG. We did not rate the quality of
evidence cited but described the study design in many cases.
2. Methods
We searched the published peer-reviewed medical literature
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searched, including MEDLINE, EMBASE, Cochrane, ERIC,
and EBSCO.The search was limited to articles in English and
foreign language publications with English abstracts. Several
key words were used including uveitic glaucoma, inflam-
matory glaucoma, Posner-Schlossman syndrome (PSS), and
Fuchs heterochromic cyclitis. All retrieved articles were
cross-referenced and citations in the bibliography were
retrieved if deemed relevant. Articles displayed in the “related
articles” link on PubMed also were used when relevant.
3. Physiopathology
The mechanisms that determine an IOP increase in UG are
diverse and complex; many are often present simultaneously
in the same patient. Open-angle glaucoma (OAG) occurs as a
result of mechanical obstruction of the trabecular meshwork
by inflammatory cells, proteins, debris, fibrin, or inflamma-
tory precipitates. Additionally, direct inflammation of the
trabecular meshwork and/or the effect of corticosteroids on
the trabecular meshwork may contribute to the open-angle
mechanism of UG [1, 2]. Up to one-third of patients with
uveitis treated with corticosteroids may have elevated IOP,
and it may be difficult to distinguish between the side effects
of the corticosteroids and the underlying inflammation. A
family history of glaucoma, rheumatoid arthritis, diabetes,
and younger age are considered risk factors of a steroid
responder [1].
Secondary angle closure can result from synechial clo-
sure, neovascularization of the chamber angle, or seclusion
pupillae with subsequent appositional angle closure. Less
commonly, angle-closure glaucoma develops when inflam-
mation and edema cause ciliary body forward rotation to
close the angle, as in patients with Vogt-Koyanagi-Harada
syndrome (VKHS).
These complex interactions cause patients with UG to
have high IOP fluctuations and great variability in the
therapeutic response.
4. Classification
Some authors have proposed differentiating between hyper-
tensive uveitis and UG based on the absence or presence of
optic nerve damage, but this distinction usually is not applied
to secondary glaucomas [3]. Typical hypertensive uveitis,
such as in PSS, can cause glaucomatous damage over time in
relation to the number, duration, and intensity of the episodes
(Figure 1) [4].
5. Diagnosis
Recent improvements in the clinical evaluation of the optic
nerve and retinal nerve fiber layer (RNFL), such as scanning
laser ophthalmoscopy and optical coherence tomography
(OCT), and of the angle, such as ultrasound biomicroscopy
(UBM) and anterior segment OCT, are as relevant to UG as
to other glaucomas.
The higher IOP levels associated with UG may cause
apparent structural damage detected by optic disc imaging
that disappears when the IOP level returns to normal [3].
Optic disc imaging is a useful way to document the glaucoma
status in this type of eye, provided that media opacification
does not hamper image acquisition.
However, it is important to consider that uveitis is amajor
confounding factor in assessing the RNFL thickness. Moore
et al. reported substantial RNFL thickening in patients with
active uveitis and a thicker RNFL than expected in patients
with UG [5], probably related to breakdown in the blood-
retinal barriers and increased production of prostaglandin
analogues (PGAs). After the inflammation improves, the
retinal thickness decreases and thinning of the RNFL and
increased cupping can be observed [6]. These changes raise
concerns about the comparative value of RNFL scans as a
method for detecting and monitoring glaucomatous damage
in patients with uveitis.
Normal-appearing measurements of the RNFL thickness
in patients with UG should be interpreted cautiously in
those with elevated IOP. Physicians should recognize that
continued thinning of the RNFL and increased cupping,
despite good IOP control in such eyes, might be due to
resolution of edema of the RNFL.
Screening for glaucomatous RNFL changes in uveitis
must be performed during quiescent periods. Thinning of
the inferior quadrant suggests that glaucomatous damage
is in fact occurring [7]. Measurement of the RNFL may
facilitate detection of signs of damage before disc or visual
field changes and therefore identifies a subgroup that should
receive more aggressive treatment [7]. In addition, OCT
also has become a standard for confirming the diagnosis of
macular edema [8].
If the cornea cannot be cleared adequately, UBM and
OCT are useful for evaluating the angle [1]. UBM is valuable
for evaluating different types of angle-closure glaucoma.This
technique currently has an advantage over OCT in that
the ciliary body can be visualized as the iridocorneal angle
even in the presence of substantial corneal opacification.
Visualization of the ciliary body is particularly useful for
diagnosing chronic ocular hypotony, which paradoxically
may be a late development in patients with chronic UG.
It is also very important to evaluate closed-angle glaucoma
secondary to anterior rotation of the ciliary body. Anterior-
segment OCT also may be helpful to evaluate the length
and position of glaucoma drainage device tubes and their
relationship with the corneal endothelium [9] as well as to
evaluate filtering bleb in eyes that have undergone filtration
surgery [10, 11].
6. Epidemiology and Etiology
Glaucoma occurs in around 20% of all patients with chronic
uveitis [2]. The incidence and clinical appearance of UG
differ according to the disease etiology. The etiology of
uveitis varies among different ethnicities and even among
regions of the same country [12]. Higher rates are reported
in those with rheumatoid arthritis-associated iridocyclitis,
Fuchs heterochromic iridocyclitis (27%), sarcoidosis (34%),
herpes simplex keratouveitis (54%), zoster uveitis (38%) [2],
Lyme-associated uveitis, cancer-associated uveitis [13], juve-
nile idiopathic arthritis (JIA) (12–35%), Behçet’s disease, pars
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Age
Rate of progression: −14.5 ± 8.5%/year (95% confidence)
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1 12/21/20113:53:41 AM 4000-1329 7/10 71 79 78 0.88 0.64 0.73 0.155
2 2/16/20121:56:38 AM 4000-1329 R2 6/10 73 83 81 0.88 0.61 0.73 0.130
3 4/22/20133:11:13 AM 4000-1386 R2 6/10 62 56 85 0.60 0.75 0.86 0.230
4 10/7/201310:11:39 AM 4000-1386 R1 6/10 61 60 82 0.65 0.73 0.82 0.190
5 1/7/201411:49:33 AM 4000-1386 R2 6/10 55 57 67 0.75 0.69 0.84 0.137
6 4/3/20141:47:18 PM 4000-1386 R2 7/10 54 51 68 0.72 0.69 0.86 0.137
7 8/28/20141:26:15 PM 4000-1386 R2 6/10 52 52 62 0.64 0.72 0.85 0.159















Figure 1: Visual field and OCT progression after recurrent episodes of UG (VFI: Visual Field Index).
planitis, sympathetic ophthalmia, and syphilis [2]. Acute IOP
elevation is also typical in PSS. Some signs are characteristic
of specific etiologies and may be helpful to establish a correct
diagnosis (Figure 2).
6.1. Fuchs Heterochromic Uveitis (FHU). FHU was described
as the triad of anterior uveitis, heterochromia, and cataract.
It is unilateral in 90% of cases and the affected eye is
the hypochromic one (Figure 3). The uveitis is chronic and
low-grade, without synechiae and with typical small stellate
keratic precipitates [1]. Microhyphema after paracentesis,
gonioscopy or tonometry (Amsler’s sign) is typical of FHU
and related to the anomalous vessels in the angle chamber.
OAG is present in 13% to 59% of cases. Initially, it can respond
to anti-inflammatory and medical treatment, but a filtering
surgery is commonly needed to control the IOP. FHU is
considered to have a higher risk of failure when associated
with UG [14].
Chee and Jap reported that 41.7% of eyes with presumed
FHU are cytomegalovirus- (CMV-) positive. Patients with
CMV-positive presumed FHU are more likely to be men, be
older at diagnosis, and have nodular endothelial lesions [15].
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Figure 2: UG diagnosis flowchart.
(a) (b)
Figure 3: Fuchs heterochromic uveitis in one patient. The right eye is normal. The left hypochromic eye is affected.
6.2. PSS. Glaucomatocyclitic crisis, or PSS, presents typically
with unilateral recurrent episodes of mild cyclitis with a
few fine keratic precipitates and elevated IOP in the range
of 40 to 60mmHg during episodes that usually resolves
spontaneously. The IOP is normal between attacks and the
angle is open [15, 16]. The course is commonly benign, but
about 25% of patients can develop glaucomatous damage if
the number of episodes or the disease duration is sufficiently
long (Figure 1) [4].
In two recent studies, more than 50% of aqueous humour
samples from eyes with PSS were positive for CMV by
polymerase chain reaction (PCR) analysis [15, 17]. Severe
endothelial cellular loss and a higher number of eyes requir-
ing glaucoma filtering surgery were observed in patients with
CMV-positive PSS [17].
6.3. Herpetic Uveitis. UG is the most common complication
in patients with herpetic uveitis and it is typically unilateral.
An acute increase in IOP in the presence of active iridocyclitis
is the hallmark of a herpetic etiology, associated with herpes
simplex virus or varicella zoster virus. Inflammation of the
trabecular meshwork has been proposed as the cause of IOP
elevations and is supported by normalization of the IOP after
corticosteroid treatment [1]. Diffuse or sectorial iris atrophy
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Figure 4: Sectorial iris atrophy is typical of herpetic uveitis.
is a characteristic of herpetic iritis (Figure 4). The presence
of corneal stromal opacities is typical of herpetic stromal
keratouveitis and can assist in the etiologic diagnosis. In some
severe cases, posterior synechiae andfibrin depositionmay be
present [1].
6.4. JIA. Most patients who develop uveitis have oligoarticu-
lar JIA [18]. About one-third of patients with JIA-associated
uveitis develop secondary ocular complications such as pos-
terior synechiae, cataract, band keratopathy, glaucoma, or
macular edema [18]. The prevalence of glaucoma or ocular
hypertension in JIA-associated uveitis has been reported
to range from 14% to 42% [1]. Patients with persistent
low-grade intraocular inflammation are at the greatest risk
for developing glaucoma. OAG and secondary closed-angle
glaucoma as a result of formation of posterior synechiae
can be present in JIA uveitis. Immunomodulatory therapy
such as methotrexate is often necessary to treat the chronic
iridocyclitis associated with JIA [18, 19].
6.5. VKHS. VKHS typically presents as bilateral panuveitis
with dermatologic and central nervous system manifesta-
tions. Glaucoma can be present in 18% to 38% of cases.
Themanagement of the closed-anglemechanism is especially
challenging because edema and anterior rotation of the ciliary
body can be present, and these cases do not respond to
iridotomy.
6.6. Postoperative UG. UG can be present after complicated
cataract surgery. Secondary glaucoma can develop because
of retained nuclear or cortical lens fragments. Malposition
or subluxation of an intraocular lens (IOL) can determine
pigment dispersion and elevated IOP. The uveitis-glaucoma-
hyphema syndrome is the typical clinical picture and IOL
explantation may be required in some cases [20].
7. Management
Uveitis is a complex multifactorial ocular inflammatory dis-
ease process that often requires a multidisciplinary approach.
Successful management requires simultaneous treatment of
both uveitis and IOP elevation. Adequate control of inflam-
mation is mandatory and a current mistake is to undertreat
the uveitis to avoid the corticosteroid-induced IOP elevation.
This conservative approach can result in trabecular mesh-
work damage secondary to the inflammatory process.
Etiologic treatment may be helpful in some specific
etiologies such as herpetic keratouveitis. When present, the
angle-closure component must be managed [3].
7.1. Anti-Inflammatory Treatment. The first step in UG man-
agement is controlling the inflammation, which minimizes
the adverse effects of the inflammatory process. In some
cases, controlling the uveitis may help reduce the IOP.
Patients treated aggressively with anti-inflammatory therapy
have a better clinical course of the UG [1].
Corticosteroids are the preferred anti-inflammatory drug
used to treat uveitis. It is advisable to start with strong topical
corticosteroids such as prednisolone acetate, but periocular
or systemic corticosteroids may be required in refractory
cases [1, 3]. Rimexolone and loteprednol induce the IOP
steroid response less often; however, the anti-inflammatory
effect is weaker and in UG it is necessary to use stronger cor-
ticosteroids.The chronic inflammation commonly present in
FHU does not require continued anti-inflammatory treat-
ment, but it could be useful to use corticosteroids in acute
exacerbations of uveitis with transient IOP spikes [21].
Nonsteroidal anti-inflammatory drugs are not usually
helpful for treating UG and can partially block the hypoten-
sive effect of some glaucoma medications such as latanoprost
and brimonidine [2, 22].
In corticosteroid responders, immunosuppression with
drugs such as cyclosporine, azathioprine, methotrexate, or
anti-tumor necrosis factor-alpha antibody therapy may be
necessary. In these cases, coordinationwith a uveitis specialist
or rheumatologist who is more comfortable in initiating or
adjusting systemic immunomodulatory therapy is advised
[2].
Cycloplegic agents must be used with anti-inflammatory
treatment in some acute uveitic episodes, with the exceptions
of PSS and FHU. In case of peripheral anterior synechiae with
permanent angle closure, mydriatics and cycloplegics may be
contraindicated.
7.2. Antiviral Treatment. Antiviral treatment should be pre-
scribed to treat specific etiologies such as herpes simplex
or varicella zoster. Topical antiviral therapy is indicated in
patients with keratouveitis to prevent viral replication during
treatment with topical steroids, but it is considered ineffec-
tive in herpetic uveitis. Along with management of glau-
coma, long-term antiviral prophylaxis such as oral acyclovir,
valacyclovir, or famciclovir usually is required to prevent
recurrences. Acyclovir 800mg twice daily or valacyclovir
prophylactically for patients with herpes simplex disease
and double the dose for varicella zoster disease have been
recommended [1].
Aqueous analysis by PCR recently has been positive for
CMV in some patients with PSS and Fuchs heterochromic
iridocyclitis [15]. Considering that more than 50% of patients
with PSS will be positive for CMV after PCR analysis of
the aqueous humor, ganciclovir and valganciclovir have been
proposed as etiologic treatments.
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Topical ganciclovir effectively clears the viral load, helps
control IOP, and preserves the corneal endothelium of
patients with CMV-positive PSS. The regimen used was
topical 2% ganciclovir solution every 2 to 3 hours daily
as induction therapy and every 4 hours for long-term
maintenance therapy. All CMV-infected eyes treated with
continuous topical 2% ganciclovir had undetectable CMV
levels at subsequent analyses. During follow-up, the average
number of antiglaucomatous agents decreased but a similar
frequency of IOP spikes occurred in both groups.
Patients with CMV-positive eyes with a disease duration
exceeding 5 years were likely to require glaucoma surgery. All
patients undergoing surgery had CMV-negative PCR results
during the IOP attack but had severe peripheral anterior
synechiae and pigment clogging [17].
In the same way, 11 patients with PSS with positive CMV
PCR analysis of the aqueous humor were treated with 900mg
of valganciclovir twice daily for 3 weeks followed by 450mg
twice daily for a mean period of 20 months. In the first week
of treatment, the IOP decreased significantly and remained
stable during the entire treatment period. However, two
patients had a recurrence after the drug was discontinued.
No side effects of therapy developed. Long-term oral therapy
with valganciclovir seems to lower the recurrence rate in
patients with clinically diagnosed PSS and positive CMV
aqueous humor [23].
7.3. Antiglaucomatous Drugs. In UG, the effectiveness of
antiglaucomatous medical treatment may vary in the pres-
ence of inflammation or when combined with mandatory
steroid treatment. Less topical medication may be absorbed
in the presence of inflammation, and the IOP-lowering effect
of most ocular hypotensive agents can vary markedly in
uveitis, ranging from no response to profound reductions
(70%–80%) with relatively small amounts of ocular hypoten-
sive medication in the occasional uveitic eye with very labile
IOP levels [2].
No clinical evidence supports a first-line therapy for UG.
Traditionally, topical beta-blockers and CAIs have been con-
sidered the first-line agents to treat increased IOP associated
with uveitis. PGAs can be used as first-line therapy in UG
with controlled uveitis [24, 25]. Systemic CAIs should be
considered if topical medications fail to achieve the desired
effect [1].
7.3.1. Beta-Blockers. Nonselective topical beta-adrenergic
antagonists are considered the first-line agents used to
decrease IOP in patients with UG without systemic con-
traindications [3]. Metipranolol, including the unpreserved
preparation, should be avoided because of its associationwith
anterior granulomatous uveitis [3, 26, 27].
7.3.2. PGAs. Controversy exists concerning the use of PGAs
in patients with uveitis due to the theoretically higher risk
of anterior uveitis, blood-aqueous barrier disruption, cystoid
macular edema (CME), and reactivation of herpes simplex
keratitis. However, in a comparative study on the efficacy
and safety of latanoprost against a fixed combination of
brimonidine and timolol in patients with UG, latanoprost
was at least as effective as the fixed combination and there
were no differences in the rate of inflammatory recurrences
and incidence rates of CME between the treatments. The
authors concluded that latanoprost is as safe and effective as
the fixed combination of brimonidine and timolol for treating
UG [24].
A paradoxical reaction after treatment with latanoprost
was reported in three patients with UG with increased IOP
and recurrent inflammation 7 to 16 days after rechallenging
with topical latanoprost. However, all patients had undergone
a previous complicated intraocular surgery [28].
Another concern is related to the possible induction of
chronic conjunctival inflammation that may have a negative
effect in future filtering surgeries. After studying conjunctival
cells by impression cytology for inflammatory markers by
flow cytometry, Taylor et al. found that the use of topical
PGAs does not induce conjunctival inflammation over that
already present in patients with UG. This finding supports
the use of topical PGAs in patients with UG, indicating that
their use is unlikely to adversely affect subsequent glaucoma
filtration surgery through induction of chronic conjunctival
inflammation [29].
In summary, PGAs and prostamides may be first-line
therapy choices in patients with UG, especially in cases of
quiescent uveitis without previous complicated intraocular
surgery or preexisting CME [1, 24, 25]. In eyes with a history
of herpetic keratitis or keratouveitis, PGAs are best avoided
[25].
7.3.3. CAIs. The IOP-lowering effect of topical CAIs varies
greatly in patients with uveitis [27]. A potential advantage is
the possible positive effect in preventing and treating CME
coexistent with UG.
Dorzolamide significantly inhibits CAI activity. Irre-
versible corneal decompensation has been described after
topical administration of dorzolamide in patients with under-
lying corneal endothelial compromise. In patients with pre-
existing corneal endothelial injury, topical CAIs must be
avoided [3].
Acetazolamide is used frequently to manage acute IOP
elevations in combination with other antiglaucomatous
drugs. It is especially helpful in preparing patients for filtering
surgery.
Although an anecdotal case report has reported the
additive effect on IOP reduction with the concomitant use
of topical and systemic CAIs [30], the general trend is to
consider that topical CAIs do not have an additive effect to
maximal oral doses of acetazolamide.
7.3.4. Alpha-2 Adrenergic Agonists. Currently, brimonidine,
an alpha-2 adrenergic agonist, is considered a useful second-
line therapy for patients with glaucoma and it is most often
used in combined therapy.
Granulomatous anterior uveitis has been described after
long-term use of apraclonidine and brimonidine. Most cases
developed about 1 year after alpha-2 adrenergic treatment
and typically an allergic reaction preceded the anterior uveitic
episode and the patients had not stopped the treatment after
this episode (Figure 5).
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Figure 5: Granulomatous uveitis after long-term apraclonidine
treatment.
Some cases recurred after rechallenging with brimoni-
dine, confirming the causal relationship. Typically, the inflam-
mation resolves rapidly after stopping the alpha-2 adrenergic
treatment and with use of topical corticosteroids [31, 32].
When using an alpha-2 adrenergic agonist, it is important
to be alert for the first signs of intolerance or allergic reaction
and immediately stop treatment. Anterior uveitic reactivation
is possible after brimonidine treatment in patients with UG.
7.3.5. Cholinergic Agents. Cholinergic agents or miotics gen-
erally are contraindicated for treating UG because of the
potential exacerbation of inflammation via blood-aqueous
barrier breakdown. In addition, miotics promote develop-
ment of posterior synechiae, and in patients with synechial
angle closure these drugs are generally ineffective given
their mechanism of action of increasing trabecular aqueous
outflow [27].
7.4. Laser Trabeculoplasty. The common angle-closuremech-
anism in many cases of UG may preclude the use of argon
laser trabeculoplasty (ALT). There is also concern about the
risk of exacerbating inflammation and trabecular meshwork
damage after ALT. ALT currently is not recommended for
treating UG [3].
Selective laser trabeculoplasty (SLT) has been suggested
as an alternative treatment for UG. Siddique et al. reported
a significant IOP reduction after SLT in naı̈ve eyes with
UG (19.8% after a 1-year follow-up). SLT was less effective
in eyes that underwent a previous glaucoma surgery [1].
However, the complete results and complications have not
been published, and currently there is insufficient clinical
evidence to recommend SLT to treat UG.
7.5. Surgery. If medical management fails to control IOP,
surgery is the next step. About 30% of eyes with UG may
require surgery [33]. The surgical success rates in UG varies
markedly (50%–100%) [13]. There is a consensus that the
surgical success rate of filtering surgery is lower for eyes with
UG compared with POAG.
As a rule, suppression of inflammation in the periopera-
tive period significantly improves outcomes [12]. Regardless
of the surgical modality chosen, all patients require metic-
ulous control of inflammation preoperatively and vigilant
monitoring for reactivation postoperatively. Otherwise, the
ciliary body can be damaged by inflammation and/or mit-
omycin C (MMC) use during filtering surgery. Surgeons
should exercise caution when recommending irreversible
filtering glaucoma procedures and in concomitant use of
antimetabolites to avoid prolonged hypotony and the risk of
phthisis bulbi.
Preoperatively,although good control of intraocular inflam-
mation for a number of months is ideal, filtration surgery
rarely is an elective procedure, and a regimen of preoper-
ative topical or systemic corticosteroid treatment (e.g., 0.5
to 1mg/kg/day of oral prednisolone) is useful to reduce
intraocular inflammation and the inflammatory cells in the
conjunctiva [2].
Intraoperatively, antifibrotics during filtering procedures
may retard postoperative wound healing. Alternatively, an
infraorbital depot of 40mg of methylprednisolone or intrav-
itreal 4mg of triamcinolone can be administered at the
conclusion of surgery [2].
Postoperatively, a major challenge to successful filtration
surgery for uveitis is the accelerated healing that occurs in the
presence of postoperative inflammation. However, there is no
way to completely eliminate postoperative inflammation and
the severity of uveitis may increase postoperatively.
The significant risk factors for surgical failure are male
sex, age younger than 45 years, nongranulomatous uveitis and
prolonged postoperative inflammation [12].
The choice of the most appropriate surgery depends on
patient age, inflammatory activity, previous ocular surgeries,
conjunctival scarring, pathophysiology of the IOP elevation,
surgeon experience, and postoperative IOP goal.
7.5.1. Trabeculectomy. Classically, trabeculectomy has been
the procedure of choice for treating UG, with the exception
of aphakic eyes, neovascularization, or poor visual function
[3]. Success rates from 50% to 100% have been reported
after trabeculectomy to treat UG [13]. Poor success rates with
trabeculectomy performed without antiproliferatives have
been reported in UG; the standard of care is adjunctive 5-
fluorouracil (FU) orMMC in these patients [1]. InUG,Towler
et al. reported that after 5 years follow-up, 50% of eyes that
underwent trabeculectomy with 5-FU were controlled versus
only 30% of eyes in which 5-FU was not applied [34].
Trabeculectomy withMMC is less effective in UG than in
POAG. However, Kaburaki et al. did not found differences in
the efficacy and safety of trabeculectomy with MMC as the
initial ocular surgery in inactive uveitis and POAG, although
hypotonic maculopathy was more common in UG [35].
Granulomatous uveitis and previous cataract surgery are
considered risk factors for failure after trabeculectomy with
MMC [36]. In granulomatous uveitis, fibrotic tissue and
granuloma containing Langhans giant cells accumulate in the
trabecular meshwork and Schlemm’s canal and may obstruct
the filtering pathway created by trabeculectomy.
Trabeculectomy with MMC in patients with UG has
been associated with a higher risk of cataract progression.
Regarding the cataractogenic effect of trabeculectomy [37],
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chronic ocular inflammation, and continuous corticosteroid
treatment also may contribute to more rapid progression of
cataract.
The most common complications after trabeculectomy
in patients with UG are recurrent inflammation (17.6%)
and hypotony (11.8%). Meticulous control of inflammation
preoperatively and vigilant monitoring for reactivation is
mandatory. Considering the associated damage to the ciliary
body in some patients with uveitis, prudent use of MMC is
advisable to avoid prolonged postoperative hypotony.
Even though subconjunctival bevacizumab (Avastin,
Genentech Inc., South San Francisco, CA) has been used
successfully for controlling wound healing after glaucoma
filtration surgery, no data have been published on the safety
and efficacy of intraoperative use of bevacizumab as adjunct
to trabeculectomy in UG [1].
7.5.2. Ex-PRESS Mini-Glaucoma Shunt. The Ex-PRESS glau-
coma filtration device (Alcon Laboratories, Fort Worth,
Texas, USA) is a metallic implant that provides an artificial
channel to drain aqueous into the subconjunctival space.This
technology is less invasive than traditional trabeculectomy.
The Ex-PRESS shunt does not require a sclerectomy or
peripheral iridectomy; hence, there is less inflammation and
risk of blockage of the inner window by fibrin, blood, or iris.
All of these factors can be advantageous in UG.
In a small preliminary case series of five patients, Lee et
al. reported the safety and efficacy of the Ex-PRESS glaucoma
filtration device with intraoperative MMC for use in UG.
The complete and qualified success rates were 80% and
100%, respectively, after 6-month follow-up. Postoperative
hypotony due to ciliary shutdown occurred in 20% of cases,
one of which was complicated by choroidal detachment
and long-term hypotony maculopathy [38]. Larger trials are
warranted to establish the long-term efficacy and safety of the
Ex-PRESS for the treating UG.
7.5.3. Nonperforating Deep Sclerectomy (NPDS). This is an
attractive alternative for glaucoma surgery in UG and in
steroid-induced IOP elevations with an open angle in that
it avoids anterior chamber entry, iris manipulation, and
prolonged hypotony. The absence of iris manipulation is of
special importance in patients with uveitis and may reduce
the risk of postoperative inflammation and hyphema. These
complications have been associated with a greater risk of
failure after filtering surgery.
The integrity of the trabeculodescemetic window allows
controlled outflow of aqueous humor, which reduces the risk
of profound and long-term hypotony, and it also has been
postulated to prevent egress of cytokines and inflammatory
mediators from the anterior chamber into the subconjuncti-
val space, which reduces the risk of inflammation, scarring,
and failure of filtering surgery [39–41].
There is increasing evidence that NPDS is probably more
appropriate for UG [40–43]. Al Obeidan et al. published
the largest prospective study of 33 consecutive eyes with
uncontrolled UG treated with NPDS withMMC and implan-
tation of either the T-Flux implant (Ioltech, La Rochelle,
France) or SK gel (Corneal Laboratories, Paris, France). After
a mean follow-up of 33.2 ± 19.8 months, the IOP decreased
from a mean preoperative value of 37.2mmHg to a mean
postoperative value of 14.7mmHg. Complete success was
achieved in 72.7% of eyes and qualified success in 21.2%
of eyes. Neodymium (Nd):YAG laser goniopuncture was
performed in 36.4%of eyes, afterwhich the iris adhered to the
trabeculodescemetic window in one patient. Postoperative
complications included cataract progression (27.3%), tran-
sient hypotony (18.2%), shallow choroidal effusions (12.1%),
and hypotony with persistent maculopathy, hyphema, and
decompression retinopathy (3%) [41]. These complications
may bemore prevalent in patients withUG than in those with
POAG.
Regarding trabeculectomy, Dupas et al. showed in a
retrospective study that similar midterm control of IOP was
obtained by either trabeculectomy with MMC (0.4mg/mL
for 3 minutes) or NPDS with MMC (0.4mg/mL for 3 min-
utes) and the T-Flux implant, with similar success rates at 12
months. No significant difference between the results of these
procedures was found for postoperative complications or the
need for reoperation. However, NPDS required many more
postoperative adjustments than trabeculectomy (goniopunc-
ture and needling) and trabeculectomy induced marked,
though transient, worsening of intraocular inflammation.
Visual acuity scores and postoperative cataract progression
requiring phacoemulsification were similar in both groups
[42].
Although randomized prospective comparative studies of
these two procedures are still necessary, this study suggested
that NPDS (with simultaneous use of an implant and MMC)
and trabeculectomy with antiproliferative agents are both
effective for managing UG. NPDS generates less inflamma-
tion during the early postoperative follow-up but requires
closemonitoring for appropriate adjustment of IOP-lowering
interventions, such as goniopuncture or needling. However,
trabeculectomy leads to high transient postoperative inflam-
mation but facilitates direct IOP reduction with very few
postoperative adjustments and might be indicated in cases in
which close monitoring is difficult [42].
More controversial is the indication of filtering surgery in
PSS. Campana et al. reported a patient with PSS who under-
went NPDS with MMC and the T-Flux implant. Goniopunc-
ture was required 9 months after NPDS. The IOP remained
15 to 16mmHg without topical treatment and no subsequent
episode of ocular inflammation 6 years after Nd:YAG laser
goniopuncture [44]. In our personal experience, NPDS in
PSS facilitates significant reductions in the number and sever-
ity of hypertensive peaks (unpublished data); one patient
presented with persistent hypotony maculopathy after NPDS
with MMC (Figure 6).
Amodified NPDS has been described in JIA.The authors
made two circumscribed punctures from Schlemm’s channel
into the anterior chamber, lateral to the sclerectomy. They
used MMC (0.2mg/mL) on the bare sclera for 1 minute
in all cases without an implant and reported that IOP can
be reduced sufficiently using standard trabeculectomy with
MMC andNPDSwithMMC, but trabeculectomywithMMC
maybemore effective.However, additional surgeries to adjust
the IOP were common for both groups. In aphakic children,
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Figure 6: PSS. Two small endothelial precipitates are seen. A
conjunctival filtering bleb after NPDS is seen.
the modified sclerectomy described earlier appears to be a
better technique for avoiding vitreous prolapse [45].
7.5.4. Canaloplasty. This procedure may be of special interest
in UG surgery because it acts on an important source of
outflow resistance in uveitic eyes exposed to steroids. Gluco-
corticoids increase IOP via deposition of extracellular matrix
material in the juxtacanalicular tissue, leading to thickening
of the trabecular meshwork beams, decreased intertrabecular
spaces, and a subsequent increase in outflow resistance.
Histologic analysis of UG eyes on topical steroids confirmed
the trabecularmeshwork beam thickening [46]. Canaloplasty
expands and maintains a patent Schlemm’s canal, increasing
the previously reduced intertrabecular spaces.
In a retrospective pilot study of 19 uveitic eyes, canalo-
plasty with postoperative Nd:YAG goniopuncture was a safe
and effective surgery for treating open-angle UG [28]. At the
last follow-up visit (mean follow-up time, 2.6 ± 1.1 years),
the complete success rate was 73.7% and the failure rate
was 15.5%. A 55% reduction in IOP was achieved and the
mean number of antiglaucoma drugs decreased from 3.7 ±
0.8 preoperatively to 0.4 ± 1.0 at the last follow-up. The
postoperative complications were Prolene suture erosion into
the anterior chamber (10.5%), transient hyphema (5.3%), pro-
longed hypotonousmaculopathy after goniopuncture (5.3%),
and rapid progression of cataract (5.3%).
The mean number of steroid drops was 0.5 ± 0.6 in the
preoperative period and 0.7 ± 1.4 6 months postoperatively.
Canaloplasty is a promising technique for UG, because
it expands the intertrabecular spaces, targeting an important
source of outflow resistance in uveitic eyes exposed to
glucocorticoids [33].
7.5.5. Glaucoma Drainage Devices (GDD). These devices
often are considered the first choice forUG surgery, especially
in etiologies such as JIA [47]. In patients with extensive
Figure 7: Ahmed valve tube occlusion by fibrin exudation in a
patient with UG.
peripheral anterior synechiae, the tube should be placed in
the sulcus rather in the anterior chamber to avoid endothelial
trauma.
Owing to its unidirectional valve mechanism, implanta-
tion of Ahmed glaucoma valve (AGV) (AGV; New World
Medical Inc., Rancho Cucamonga, CA, USA) may be more
convenient because of the lower risk of immediate post-
operative hypotony. Success rates of 77% and 50% have
been reported with AGV in UG after 1 and 4 years of
follow-up, respectively [48]. Encapsulated bleb (43%), tran-
sient hypotony (43%), and hyphema (21%) are the short-
term complications most commonly described after AGV
implantation in UG [48, 49]. Occlusion of the tube by
inflammatorymaterials and corneal decompensation also has
been associated with AGV implantation in eyes with UG
(Figure 7) [48].
Preoperative use of corticosteroids may improve the
surgical success of the AGV in UG. Mata et al. suggested
prescribing 1mg/kg/day prednisone preoperatively until the
inflammation is controlled. In the postoperative period, oral
corticosteroids are taped tapered over 4 weeks [50].
Nonvalved GDDs such as the Baerveldt implant (Abbott
Laboratories Inc., Abbott Park, IL, USA) have been recom-
mended. The cumulative probability of success was greater
with a Baerveldt GDD than after trabeculectomy for UG.
There was a significantly higher frequency of early com-
plications in the trabeculectomy group compared with the
GDD group; however, no significant differences were seen
in the frequency of late postoperative complications between
groups.The most common postoperative complications after
implantation of a Baerveldt GDD were hypotony and CME,
but there were no differences between the Baerveldt implant
and trabeculectomy. The authors concluded that implanta-
tion of the Baerveldt GDD was more likely to maintain IOP
control and avoid reoperation for glaucoma compared with
trabeculectomy with antifibrotic therapy in eyes with chronic
inflammatory glaucoma [13].
The Molteno aqueous shunt (Molteno Ophthalmic Ltd.,
Dunedin, New Zealand) also has been recommended for
primary surgical treatment in UG. Vuori reported a qual-
ified success rate of 85% after 4-year follow-up. The IOP
decreased continuously during the first year postoperatively,
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and the medication was slowly tapered even up to 3 years
postoperatively. Therefore, the author suggested postponing
further surgical interventions during the first postoperative
year after Molteno implantation in UG, even if the IOP is not
controlled. Persistent hypotony was present in 6.66% of cases
and corneal decompensation in 3.33% of cases [51].
In summary, GDDs are one of the preferred first-line
surgeries in UG. The AGV, Molteno, and Baerveldt GDDs
have been used with good success rates, but no studies have
compared if nonvalved or valved GDDs are preferable in UG.
7.5.6. iStent. In a mixed series of secondary glaucoma
cases including four cases with steroid-induced glaucoma,
Buchacra et al. reported that the Glaukos iStent (Glaukos
iStent, Glaukos Corporation, Laguna Hills, CA) is a safe and
effective surgical option for secondary OAG, but they did not
present isolated data for steroid glaucoma [52]. Good results
were achieved with Glaukos trabecular bypass in one case of
IOP elevation induced by steroid treatment after laser in situ
keratomileusis [53].
After preliminary studies, the Glaukos iStent may be an
attractive alternative for steroid-induced glaucoma, consid-
ering themicroinvasive and reversibility characteristics of the
procedure, although larger well-designed studies are needed
to confirm this conclusion.
7.5.7. Trabectome Surgery. Shimizu et al. performed trabec-
tome surgery in a subgroup of patients with UG and reported
a success rate of 75%, but more details about the safety and
efficacy of trabectome in UG were unavailable [12].
7.5.8. Goniotomy. The procedure has been suggested for
refractory glaucoma associated with chronic childhood
uveitis [54–56]. The largest series included 54 goniotomies
in 40 eyes, with the predominant diagnosis of juvenile
rheumatoid arthritis (mean age at surgery, 10.3 years). Overall
surgical success was achieved in 72% of cases (complete suc-
cess, 55%). Phakic eyes, fewer peripheral anterior synechiae,
age younger than 10 years, and eyes with no previous
surgery had significantly better outcomes.Themost common
postoperative complication was mild and transient hyphema
(80%) [55].
Goniosurgery is low risk and effective for refractory
glaucoma complicating chronic childhood uveitis. For some
authors, it should be considered the surgical procedure of
choice for this condition, although almost half of patients
will need glaucoma treatment postoperatively. The surgical
outcome is affected adversely by increased age, peripheral
anterior synechiae, previous surgeries, and aphakia [55].
However, goniotomy requires considerable skill and experi-
ence and is best avoided by specialists who do not perform it
regularly [3].
Randomized comparative studies are needed to deter-
mine the efficacy and safety of goniotomy compared with
trabeculectomy or GDD surgery.
7.5.9. Cyclophotocoagulation. Cycloablative techniques can
be used to decrease aqueous production by destruc-
tion of the ciliary body using transscleral or intraocular
diode or Nd:YAG laser cyclophotocoagulation. Unfortu-
nately, cycloablative procedures can exacerbate inflammation
and lead to postoperative hypotony and phthisis bulbi. The
rate of hypotony after cyclodiode laser in uveitis (19%) is
higher than in any other secondary glaucomas [2].
Schlote et al. reported a series of 22 patients who
underwent transscleral diode laser cyclophotocoagulation
(TDLC) forUGor scleritis-associated glaucoma.The IOPwas
controlled in 77.3% of eyes, although 63.6% of cases needed
more than one treatment with TDLC. The investigators
did not observe reactivation of inflammation, persistent
hypotony, or phthisis bulbi in any case [57]. Good results
also were reported in a case of UG secondary to JIA treated
with TDLC [58]. Although preliminary studies have reported
encouraging results with TDLC in UG, it should be the
last resort for refractory glaucoma in eyes with poor visual
potential inwhich conventional drainage surgery has failed or
is impossible because of the ocular anatomic characteristics.
7.5.10. Cataract and UG Surgery. Cataract is very common
in patients with uveitis. The optimal sequence of surgery
with concomitant cataract and UG is controversial. Cataract
surgery can compromise the success of trabeculectomy [59],
but combined glaucoma and cataract surgery increases the
risk of postoperative inflammation andmay be less successful
than isolated filtering procedures [3, 14].
If combined glaucoma and cataract surgery is indicated,
good control of the inflammation is mandatory preoper-
atively and postoperatively. The use of antimetabolites at
the time of combined surgery reduces the proliferative
response [60]. A meticulous and minimally invasive surgical
procedure also can help increase the surgical success, but
the evidence is insufficient to recommend a specific filtering
surgery for combined procedures in this kind of patient.
It is also essential to be alert for detecting and treating
postoperative complications such as hypotony, athalamia,
and choroidal detachment. Stronger and longer postoperative
steroid treatment usually is required. Intensification of anti-
inflammatory treatment may be necessary in case of recur-
rent uveitis.
7.5.11. Iridotomy. Nd:YAG laser peripheral iridotomies are
indicated in cases of iris bombé and angle closure secondary
to posterior synechiae (Figure 8). In UG, Nd:YAG laser
iridotomy has an increased incidence of failure (61% in some
retrospective studies) [61]. Spencer et al. reported that the
median survival of Nd:YAG peripheral iridotomy was 85
days, with most failures occurring within the first 20 days.
Those investigators recommended multiple (at least two)
or large iridotomies (Figure 9), aggressive treatment with
topical steroids and cycloplegics, and close monitoring of
patients with frequent early review. If the iridotomy closes,
there should be early consideration for a surgical peripheral
iridectomy [61].
Recurrent herpetic keratouveitis has been described after
argon laser iridotomy [62] and after Nd:YAG laser periph-
eral iridotomy [63]. The causal relationship is difficult to
establish because patients were being treated with topical
corticosteroids and in one case with latanoprost, previously
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Figure 8: Iris bombé and pupillary seclusion in a patient with UG.
Peripheral iris burns after argon laser iridoplasty are seen.
Figure 9: Iris bombé after two Nd:YAG laser iridotomies (arrows).
related to recurrent keratouveitis. Both cases resolved with
oral acyclovir and discontinuation of latanoprost. Preventive
treatment with oral acyclovir has been suggested if iridotomy
is required in patients with UG associated with herpes virus.
Most studies that have reported the outcomes of tra-
beculectomy or GDD in uveitic eyes are not specific to
uveitis-associated angle closure, and this warrants fur-
ther investigation in more targeted studies. As in primary
angle-closure glaucoma, phacoemulsification combined with
goniosynechialysis may be an alternative in patients with
uveitis with closed-angle glaucoma, although it is expected to
be less successful when chronic peripheral anterior synechiae
are present [47].
Other causes of secondary closed-angle glaucoma such as
anterior ciliary body rotation, annular ciliary body detach-
ment, or uveal effusion require specific surgical approaches.
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